HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

YMAB

Y-Mabs Therapeutics Inc

Last Close
May 06 • 04:00PM ET
3.86
Dollar change
-0.39
Percentage change
-9.18 		%
Healthcare • Biotechnology • USA • NASD
Peers: BMRN CLLS BLUE ADAP AGEN SRPT MRNA GSK TGTX XOMA
 | Held by: VTI IWM VXF IWO IBB VTWO SCHA VHT IWC DFAS
Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.67 Insider Own23.82% Shs Outstand44.99M Perf Week-8.10%
Market Cap174.77M Forward P/E- EPS next Y-1.00 Insider Trans-0.14% Shs Float34.49M Perf Month-14.98%
Income-29.67M PEG- EPS next Q-0.21 Inst Own59.13% Short Float8.90% Perf Quarter-35.67%
Sales87.69M P/S1.99 EPS this Y-51.04% Inst Trans1.91% Short Ratio8.67 Perf Half Y-73.40%
Book/sh2.05 P/B1.89 EPS next Y1.08% ROA-23.95% Short Interest3.07M Perf Year-77.62%
Cash/sh1.48 P/C2.60 EPS next 5Y-15.65% ROE-30.74% 52W Range3.84 - 17.47 Perf YTD-50.70%
Dividend Est.- P/FCF- EPS past 5Y21.90% ROI-32.18% 52W High-77.90% Beta0.49
Dividend TTM- Quick Ratio3.85 Sales past 5Y37.71% Gross Margin82.84% 52W Low0.52% ATR (14)0.39
Dividend Ex-Date- Current Ratio4.16 EPS Y/Y TTM-36.40% Oper. Margin-35.58% RSI (14)38.81 Volatility8.75% 9.68%
Employees107 Debt/Eq0.01 Sales Y/Y TTM3.38% Profit Margin-33.83% Recom1.58 Target Price16.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-569.47% Payout- Rel Volume0.94 Prev Close4.25
Sales Surprise-9.25% EPS Surprise-29.20% Sales Q/Q13.41% EarningsMay 13 BMO Avg Volume354.09K Price3.86
SMA20-12.24% SMA50-18.10% SMA200-59.26% Trades Volume332,417 Change-9.18%
Date Action Analyst Rating Change Price Target Change
Apr-22-25Downgrade BofA Securities Neutral → Underperform $3
Nov-18-24Initiated Oppenheimer Outperform $23
Aug-16-24Initiated Cantor Fitzgerald Overweight $20
Jun-28-24Initiated Truist Buy $21
May-10-23Upgrade Wedbush Neutral → Outperform $5 → $13
Apr-03-23Downgrade Guggenheim Buy → Neutral
Jan-27-23Downgrade Morgan Stanley Equal-Weight → Underweight $4
Jan-05-23Downgrade Cowen Outperform → Market Perform
Dec-02-22Downgrade BofA Securities Buy → Neutral $23 → $5
Dec-02-22Downgrade BofA Securities Buy → Neutral
Show Previous Ratings
Today 07:05AM
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
(GlobeNewswire) -9.18%
Apr-30-25 10:01AM
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
(Zacks)
Apr-29-25 10:01AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
(Zacks)
Apr-27-25 03:00PM
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
(GlobeNewswire)
Apr-25-25 07:35AM
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
(GlobeNewswire)
04:35PM Loading…
Apr-11-25 04:35PM
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity
(Seeking Alpha) +11.03%
Mar-05-25 02:04AM
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...
(GuruFocus.com)
01:34AM
Q4 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-04-25 07:50AM
Y-mAbs announces publication of Phase 2 interim results on naxitamab
(TipRanks)
07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Mar-03-25 07:30AM
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
(GlobeNewswire) -6.65%
07:21AM
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Report Preview: What To Look For
(GuruFocus.com)
Feb-25-25 10:00AM
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
(Zacks)
Feb-20-25 04:05PM
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
(GlobeNewswire) -5.92% -5.30%
07:30AM Loading…
Feb-06-25 07:30AM
Y-mAbs to Present at the Oppenheimer 35 Annual Life Sciences Conference
(GlobeNewswire)
Feb-04-25 09:35AM
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Feb-03-25 09:35AM
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-31-25 07:35AM
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
(GlobeNewswire)
Jan-11-25 09:49AM
Y-mAbs Therapeutics Announces Strategic Business Realignment
(TipRanks)
Jan-10-25 09:26AM
Correcting and Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire) -6.77%
09:26AM
Correcting & Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire)
07:35AM
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
(GlobeNewswire)
07:05AM
Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire)
Jan-08-25 07:25AM
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
(TipRanks)
Dec-23-24 07:30AM
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-15-24 06:04AM
Oppenheimer Predicts Up to ~580% Jump for These 2 Strong Buy Stocks
(TipRanks)
Dec-07-24 12:00PM
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
(GlobeNewswire)
Nov-27-24 07:35AM
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
(GlobeNewswire) +10.31%
Nov-09-24 06:01AM
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
(GuruFocus.com)
07:45AM Loading…
Nov-08-24 07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Nov-07-24 07:08AM
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings
(GuruFocus.com)
Nov-04-24 07:35AM
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA (naxitamab-gqgk) in Japan
(GlobeNewswire)
Nov-01-24 10:00AM
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Oct-25-24 07:05AM
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
(GlobeNewswire)
Oct-09-24 06:12PM
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...
(GuruFocus.com)
Oct-01-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in October
(GlobeNewswire)
Sep-06-24 07:30AM
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
(GlobeNewswire)
Sep-03-24 08:32AM
Y-mAbs to Participate in Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-12-24 06:33PM
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
(Motley Fool) -11.24% +8.74%
07:40AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:30AM
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-09-24 07:20AM
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners Top Holdings Now?
(Insider Monkey)
Aug-07-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in August
(GlobeNewswire)
Aug-05-24 04:05PM
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
(GlobeNewswire) -6.27%
Jul-01-24 04:05PM
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
(GlobeNewswire)
Jun-07-24 07:05AM
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
(GlobeNewswire)
Jun-05-24 07:05AM
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
(GlobeNewswire) +5.91%
Jun-01-24 08:15AM
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
(GlobeNewswire)
08:05AM
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
(GlobeNewswire)
May-09-24 11:58AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
(Insider Monkey) -5.44%
03:04AM
Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 09:57PM
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
06:12PM
Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
(GuruFocus.com)
05:55PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Apr-26-24 07:05AM
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
(GlobeNewswire)
Apr-25-24 04:05PM
Y-mAbs to Present at 2024 ASCO Annual Meeting
(GlobeNewswire)
Mar-28-24 09:55AM
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
(Zacks)
Mar-20-24 07:37AM
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
(Zacks)
Mar-14-24 09:05AM
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
(GlobeNewswire) -5.30%
Mar-12-24 09:55AM
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
(Zacks)
Mar-05-24 12:00PM
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
(Zacks)
Mar-04-24 08:45AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
(Insider Monkey) -7.28%
07:30AM
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
(GlobeNewswire)
Mar-01-24 09:42PM
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:37PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023
(GuruFocus.com)
04:05PM
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Feb-22-24 10:00AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
(Zacks)
Feb-16-24 07:30AM
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
(GlobeNewswire)
Feb-13-24 04:10AM
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
(Zacks)
Jan-02-24 04:05PM
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-13-23 04:05PM
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-12-23 01:05AM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc
(GuruFocus.com)
Dec-03-23 03:04AM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc
(GuruFocus.com)
Nov-30-23 11:04PM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB)
(GuruFocus.com)
Nov-15-23 01:14PM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript
(Insider Monkey)
01:33AM
Q3 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Nov-13-23 05:31PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational Streamlining
(GuruFocus.com) +9.84%
05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
04:05PM
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Nov-08-23 12:00PM
All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy
(Zacks)
Oct-31-23 07:05AM
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
(GlobeNewswire)
Oct-18-23 04:05PM
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
(GlobeNewswire)
Oct-17-23 04:05PM
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
(GlobeNewswire)
Oct-16-23 04:05PM
Y-mAbs Announces Publication in Cancers
(GlobeNewswire)
Sep-21-23 04:05PM
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
(GlobeNewswire)
Sep-06-23 04:05PM
Y-mAbs to Participate at Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-23-23 09:55AM
Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet
(Zacks)
Aug-13-23 06:25AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-10-23 05:15PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
(Zacks) +5.48% -9.90%
04:05PM
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-02-23 04:05PM
Y-mAbs to Participate at Upcoming Investor Conferences
(GlobeNewswire)
Aug-01-23 04:05PM
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
(GlobeNewswire)
Jul-26-23 12:35PM
Institutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year losses
(Simply Wall St.)
Jun-02-23 03:15PM
Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week
(Simply Wall St.) +5.01%
May-26-23 09:00AM
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
(GlobeNewswire)
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rossi Michael JPRESIDENT & CEOMar 07 '25Sale5.203,91720,368137,083Mar 11 08:17 PM
Gad ThomasCHIEF BUSINESS OFFICERMar 07 '25Sale5.2310,81056,536202,721Mar 11 08:15 PM
Rajah VigneshOfficerMar 07 '25Proposed Sale5.204,94625,743Mar 07 04:40 PM
Smith Susan LauraOfficerMar 07 '25Proposed Sale5.265,52829,100Mar 07 04:36 PM
Gad ThomasOfficerMar 07 '25Proposed Sale5.2310,81056,547Mar 07 04:32 PM
Rossi Michael JOfficerMar 07 '25Proposed Sale5.203,91720,388Mar 07 04:26 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 19 '24Option Exercise4.3822,831100,000181,531Sep 20 04:15 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 13 '24Sale13.4765,000875,55097,681Sep 17 08:05 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 16 '24Sale12.9730,000389,10067,681Sep 17 08:05 PM
Thomas GadOfficerSep 13 '24Proposed Sale13.74100,0001,374,000Sep 13 04:19 PM
Ber GerardDirectorSep 03 '24Proposed Sale13.8313,950192,928Sep 03 05:00 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Option Exercise4.3850,000219,00085,600Aug 30 04:15 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Sale15.3750,000768,50035,600Aug 30 04:15 PM
Lund-Hansen TorbenOfficerAug 28 '24Proposed Sale15.3750,000768,432Aug 28 05:12 PM
Wilms JorisSVP & CHIEF OPERATING OFFICERAug 26 '24Sale14.695,00073,45030,600Aug 27 05:05 PM
Wilms JorisOfficerAug 26 '24Proposed Sale14.695,00073,450Aug 26 04:12 PM
Ber GerardDirectorJun 10 '24Sale12.007228,6641,608Jun 11 07:54 PM
Gad ThomasCHIEF BUSINESS OFFICERJun 10 '24Sale12.0335,000421,050197,681Jun 11 07:53 PM
Gad ThomasCHIEF BUSINESS OFFICERJun 11 '24Sale12.0035,000420,000162,681Jun 11 07:53 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 31 '24Option Exercise2.0031,37162,742242,248May 31 09:36 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 30 '24Option Exercise2.0028,62957,258239,506May 31 09:36 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 31 '24Sale12.0731,371378,648210,877May 31 09:36 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 30 '24Sale12.0328,629344,407210,877May 31 09:36 PM
Gad ThomasCHIEF BUSINESS OFFICERMay 21 '24Sale12.0025,000300,000240,032May 23 06:54 PM
Gad ThomasCHIEF BUSINESS OFFICERMay 23 '24Sale13.007,35195,563232,681May 23 06:54 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • theme settings • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.